Usefulness of Quantitative Susceptibility Mapping for the Diagnosis of Parkinson Disease

References

1. 1.↵
   2. Caslake R,
   3. Moore JN,
   4. Gordon JC, et al

   . Changes in diagnosis with follow-up in an incident cohort of patients with parkinsonism. J Neurol Neurosurg Psychiatry 2008;79:1202–07

   Abstract/FREE Full Text
2. 2.↵
   2. Drayer BP,
   3. Olanow W,
   4. Burger P, et al

   . Parkinson plus syndrome: diagnosis using high field MR imaging of brain iron. Radiology 1986;159:493–98

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Bizzi A,
   3. Brooks RA,
   4. Brunetti A, et al

   . Role of iron and ferritin in MR imaging of the brain: a study in primates at different field strengths. Radiology 1990;177:59–65

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Dexter DT,
   3. Wells FR,
   4. Lees AJ, et al

   . Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 1989;52:1830–36

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Griffiths PD,
   3. Dobson BR,
   4. Jones GR, et al

   . Iron in the basal ganglia in Parkinson's disease: an in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. Brain 1999;122(pt 4):667–73

   Abstract/FREE Full Text
6. 6.↵
   2. Wang Y

   . Principles of Magnetic Resonance Imaging: Physics Concepts, Pulse Sequences, and Biomedical Applications. http://www.createspace.com: CreateSpace Independent Publishing Platform; 2012
7. 7.↵
   2. Ordidge RJ,
   3. Gorell JM,
   4. Deniau JC, et al

   . Assessment of relative brain iron concentrations using T2-weighted and T2*-weighted MRI at 3 Tesla. Magn Reson Med 1994;32:335–41

   CrossRefPubMedWeb of Science
8. 8.↵
   2. Haacke EM,
   3. Cheng NY,
   4. House MJ, et al

   . Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 2005;23:1–25

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Gorell JM,
   3. Ordidge RJ,
   4. Brown GG, et al

   . Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 1995;45:1138–43

   CrossRef
10. 10.↵
    2. Graham JM,
    3. Paley MN,
    4. Grunewald RA, et al

    . Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. Brain 2000;123(pt 12):2423–31

    Abstract/FREE Full Text
11. 11.↵
    2. Martin WR,
    3. Wieler M,
    4. Gee M

    . Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 2008;70:1411–17

    CrossRef
12. 12.↵
    2. Langkammer C,
    3. Krebs N,
    4. Goessler W, et al

    . Quantitative MR imaging of brain iron: a postmortem validation study. Radiology 2010;257:455–62

    CrossRefPubMedWeb of Science
13. 13.↵
    2. Yao B,
    3. Li TQ,
    4. Gelderen P, et al

    . Susceptibility contrast in high field MRI of human brain as a function of tissue iron content. Neuroimage 2009;44:1259–66

    CrossRefPubMedWeb of Science
14. 14.↵
    2. Wang S,
    3. Lou M,
    4. Liu T, et al

    . Hematoma volume measurement in gradient echo MRI using quantitative susceptibility mapping. Stroke 2013;44:2315–17

    Abstract/FREE Full Text
15. 15.↵
    2. Ogawa S,
    3. Menon RS,
    4. Tank DW, et al

    . Functional brain mapping by blood oxygenation level-dependent contrast magnetic-resonance-imaging: a comparison of signal characteristics with a biophysical model. Biophys J 1993;64:803–12

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Davis TL,
    3. Kwong KK,
    4. Weisskoff RM, et al

    . Calibrated functional MRI: mapping the dynamics of oxidative metabolism. Proc Natl Acad Sci U S A 1998;95:1834–39

    Abstract/FREE Full Text
17. 17.↵
    2. Yablonskiy DA,
    3. Haacke EM

    . Theory of NMR signal behavior in magnetically inhomogeneous tissue: the static dephasing regime. Magn Reson Med 1994;32:749–63

    CrossRefPubMedWeb of Science
18. 18.↵
    2. de Rochefort L,
    3. Liu T,
    4. Kressler B, et al

    . Quantitative susceptibility map reconstruction from MR phase data using bayesian regularization: validation and application to brain imaging. Magn Reson Med 2010;63:194–206

    PubMed
19. 19.↵
    2. Liu J,
    3. Liu T,
    4. de Rochefort L, et al

    . Morphology enabled dipole inversion for quantitative susceptibility mapping using structural consistency between the magnitude image and the susceptibility map. Neuroimage 2012;59:2560–68

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Liu T,
    3. Wisnieff C,
    4. Lou M, et al

    . Nonlinear formulation of the magnetic field to source relationship for robust quantitative susceptibility mapping. Magn Reson Med 2013;69:467–76

    CrossRefPubMed
21. 21.↵
    2. Bilgic B,
    3. Pfefferbaum A,
    4. Rohlfing T, et al

    . MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping. Neuroimage 2012;59:2625–35

    CrossRefPubMed
22. 22.↵
    2. Deistung A,
    3. Schafer A,
    4. Schweser F, et al

    . Toward in vivo histology: a comparison of quantitative susceptibility mapping (QSM) with magnitude-, phase-, and R-2*-imaging at ultra-high magnetic field strength. Neuroimage 2013;65:299–314

    CrossRefPubMedWeb of Science
23. 23.↵
    2. Langkammer C,
    3. Liu T,
    4. Khalil M, et al

    . Quantitative susceptibility mapping in multiple sclerosis. Radiology 2013;267:551–59

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Lotfipour AK,
    3. Wharton S,
    4. Schwarz ST, et al

    . High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease. J Magn Reson Imaging 2012;35:48–55

    CrossRefPubMed
25. 25.↵
    2. Liu T,
    3. Surapaneni K,
    4. Lou M, et al

    . Cerebral microbleeds: burden assessment by using quantitative susceptibility mapping. Radiology 2012;262:269–78

    CrossRefPubMed
26. 26.↵
    2. Liu T,
    3. Khalidov I,
    4. de Rochefort L, et al

    . A novel background field removal method for MRI using projection onto dipole fields (PDF). NMR Biomed 2011;24:1129–36

    CrossRefPubMed
27. 27.↵
    2. Kressler B,
    3. de Rochefort L,
    4. Liu T, et al

    . Nonlinear regularization for per voxel estimation of magnetic susceptibility distributions from MRI field maps. IEEE Trans Med Imaging 2010;29:273–81

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Pauling L,
    3. Coryell CD

    . The magnetic properties and structure of hemoglobin, oxyhemoglobin and carbonmonoxyhemoglobin. Proc Natl Acad Sci U S A 1936;22:210–16

    FREE Full Text
29. 29.↵
    2. Youden WJ

    . Index for rating diagnostic tests. Cancer 1950;3:32–35

    CrossRefPubMedWeb of Science
30. 30.↵
    2. Martin WR

    . Quantitative estimation of regional brain iron with magnetic resonance imaging. Parkinsonism Relat Disord 2009;15(suppl 3):S215–18

    CrossRefPubMed
31. 31.↵
    2. Du G,
    3. Lewis MM,
    4. Shaffer ML, et al

    . Serum cholesterol and nigrostriatal R2* values in Parkinson's disease. PloS One 2012;7:e35397

    CrossRefPubMed
32. 32.↵
    2. Rossi M,
    3. Ruottinen H,
    4. Elovaara I, et al

    . Brain iron deposition and sequence characteristics in Parkinsonism: comparison of SWI, T(2)* maps, T(2)-weighted-, and FLAIR-SPACE. Invest Radiol 2010;45:795–802

    CrossRefPubMed
33. 33.↵
    2. Péran P,
    3. Cherubini A,
    4. Assogna F, et al

    . Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 2010;133:3423–33

    Abstract/FREE Full Text
34. 34.↵
    2. Baudrexel S,
    3. Nurnberger L,
    4. Rub U, et al

    . Quantitative mapping of T1 and T2* discloses nigral and brainstem pathology in early Parkinson's disease. Neuroimage 2010;51:512–20

    CrossRefPubMed
35. 35.↵
    2. Jackson JD

    . Classical Electrodynamics. 3rd ed. New York: John Wiley and Sons; 1999
36. 36.↵
    2. Jin L,
    3. Wang J,
    4. Zhao L, et al

    . Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. Brain 2011;134:50–58

    Abstract/FREE Full Text
37. 37.↵
    2. Hu MT,
    3. White SJ,
    4. Herlihy AH, et al

    . A comparison of (18)F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson's disease. Neurology 2001;56:1195–200

    CrossRef
38. 38.↵
    2. Morrish PK,
    3. Sawle GV,
    4. Brooks DJ

    . Clinical and [18F] dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry 1995;59:597–600

    Abstract/FREE Full Text
39. 39.↵
    2. Meyer GJ,
    3. Schober O,
    4. Stoppe G, et al

    . Cerebral involvement in systemic lupus erythematosus (SLE): comparison of positron emission tomography (PET) with other imaging methods. Psychiatry Res 1989;29:367–68

    CrossRefPubMedWeb of Science
40. 40.↵
    2. Volkow ND,
    3. Rosen B,
    4. Farde L

    . Imaging the living human brain: magnetic resonance imaging and positron emission tomography. Proc Natl Acad Sci U S A 1997;94:2787–88

    FREE Full Text
41. 41.↵
    2. Boska MD,
    3. Hasan KM,
    4. Kibuule D, et al

    . Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson's disease. Neurobiol Dis 2007;26:590–96

    CrossRefPubMedWeb of Science
42. 42.↵
    2. Du G,
    3. Lewis MM,
    4. Styner M, et al

    . Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease. Mov Disord 2011;26:1627–32

    CrossRefPubMed
43. 43.↵
    2. Zhang J,
    3. Tao R,
    4. Liu C, et al

    . Possible effects of iron deposition on the measurement of DTI metrics in deep gray matter nuclei: an in vitro and in vivo study. Neurosci Lett 2013;551:47–52

    CrossRefPubMed
44. 44.↵
    2. Antonini A,
    3. Leenders K,
    4. Meier D, et al

    . T2 relaxation time in patients with Parkinson's disease. Neurology 1993;43:697–700

    CrossRef
45. 45.↵
    2. Wallis LI,
    3. Paley MN,
    4. Graham JM, et al

    . MRI assessment of basal ganglia iron deposition in Parkinson's disease. J Magn Reson Imaging 2008;28:1061–67

    CrossRefPubMedWeb of Science
46. 46.↵
    2. Ulla M,
    3. Bonny JM,
    4. Ouchchane L, et al

    . Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up. PloS One 2013;8:e57904

    CrossRefPubMed
47. 47.↵
    2. Eapen M,
    3. Zald DH,
    4. Gatenby JC, et al

    . Using high-resolution MR imaging at 7T to evaluate the anatomy of the midbrain dopaminergic system. AJNR Am J Neuroradiol 2011;32:688–94

    Abstract/FREE Full Text